WuXi AppTec Reports 39.4% Revenue Growth in Q1 2026, Backlog Reaches RMB 59.77 Billion

Key Takeaways

• WuXi AppTec reported 39.4% year-over-year revenue growth from continuing operations in Q1 2026
• Adjusted non-IFRS net profit surged 71.7% to RMB 4.60 billion, demonstrating strong operational efficiency
• Backlog increased 23.6% to RMB 59.77 billion, indicating sustained client demand for pharmaceutical outsourcing services

---

WuXi AppTec Co., Ltd. (603259.SH / 2359.HK) announced robust financial results for the first quarter of 2026, with total revenue reaching RMB 12.44 billion and continuing operations revenue growing 39.4% year-over-year.

The Shanghai-based contract research, development, and manufacturing organization (CRDMO) reported adjusted non-IFRS net profit of RMB 4.60 billion, representing a 71.7% increase compared to the same period in 2025. This significant profit growth demonstrates the company’s operational leverage and efficiency improvements.

Strong Market Position in Pharmaceutical Outsourcing

WuXi AppTec’s backlog for continuing operations reached RMB 59.77 billion, up 23.6% year-over-year, indicating strong future revenue visibility. This substantial backlog reflects the growing trend of pharmaceutical companies outsourcing research, development, and manufacturing activities to specialized service providers.

The company’s performance comes amid increased global demand for pharmaceutical outsourcing services, driven by rising drug development costs and the need for specialized expertise in complex therapeutic areas.

Market Impact and Industry Trends

WuXi AppTec’s strong results highlight the resilience of the contract research and manufacturing sector. The company serves as a critical partner for pharmaceutical and biotechnology companies worldwide, providing end-to-end services from drug discovery through commercial manufacturing.

The 71.7% profit growth significantly outpaced revenue growth, suggesting improved operational efficiency and margin expansion. This performance positions WuXi AppTec favorably in the competitive CRDMO landscape.

Financial Outlook

The substantial backlog provides revenue visibility extending into future quarters, supporting investor confidence in the company’s growth trajectory. WuXi AppTec’s diversified service portfolio and global footprint continue to attract clients seeking integrated pharmaceutical development and manufacturing solutions.

The company’s Q1 2026 results reinforce its position as a leading player in the pharmaceutical outsourcing industry, with strong fundamentals supporting continued growth.

---

Frequently Asked Questions

What services does WuXi AppTec provide to pharmaceutical companies?

WuXi AppTec is a CRDMO that provides end-to-end services including drug discovery, development, testing, and manufacturing for pharmaceutical and biotechnology companies worldwide.

What does WuXi AppTec’s large backlog mean for future performance?

The RMB 59.77 billion backlog represents contracted future work, providing strong revenue visibility and indicating sustained client demand for the company’s services over coming quarters.

How does WuXi AppTec’s Q1 2026 performance compare to industry trends?

The 39.4% revenue growth and 71.7% profit increase significantly outpace typical pharmaceutical services industry growth, demonstrating WuXi AppTec’s competitive advantages and market share gains.